Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.
The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.
Links to related guidelines are provided separately:
●(See "Society guideline links: Secondary prevention of cardiovascular disease".)
●(See "Society guideline links: Obesity in adults".)
●(See "Society guideline links: Menopause".)
●(See "Society guideline links: Non-ST-elevation acute coronary syndromes (non-ST-elevation myocardial infarction)".)
●(See "Society guideline links: Chronic coronary syndrome".)
●(See "Society guideline links: Occlusive carotid, aortic, renal, mesenteric, and peripheral atherosclerotic disease".)
International
●World Health Organization (WHO): HEARTS – Technical package for cardiovascular disease management in primary health care: Risk-based CVD management (2020)
Canada
●Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE): Guideline for the prevention and management of cardiovascular disease in primary care, update (2022)
●Canadian Cardiovascular Society (CCS): Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults (2021)
●Canadian Stroke Best Practice: Acetylsalicylic acid (ASA) for prevention of vascular events, 7th edition, update (2019)
●CCS: Society position statement on smoking cessation and the cardiovascular specialist (2011)
United States
●US Preventive Services Task Force (USPSTF): Final recommendation statement on aspirin use to prevent cardiovascular disease – Preventive medication (2022)
●USPSTF: Final recommendation statement on healthy diet and physical activity for cardiovascular disease prevention in adults without cardiovascular disease risk factors – Behavioral counseling interventions (2022)
●USPSTF: Final recommendation statement on statin use for the primary prevention of cardiovascular disease in adults – Preventive medication (2022)
●American Heart Association (AHA): Scientific statement on adverse pregnancy outcomes and cardiovascular disease risk – Unique opportunities for cardiovascular disease prevention in women (2021)
●AHA: Scientific statement on weight-loss strategies for prevention and treatment of hypertension (2021)
●American College of Cardiology (ACC): Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes (2020)
●AHA: Science advisory on dietary cholesterol and cardiovascular risk (2020)
●American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR), AHA, and ACC: Scientific statement on home-based cardiac rehabilitation (2019)
●ACC/AHA: Guideline on the primary prevention of cardiovascular disease (2019)
●AHA: Special report on the use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease (2019)
●AHA: Scientific statement on health literacy and cardiovascular disease – Fundamental relevance to primary and secondary prevention (2018)
●AHA/ACC/AACVPR/American Association Academy of Physician Assistants (AAPA)/Association of Black Cardiologists (ABC)/American College of Preventive Medicine (ACPM)/American Diabetes Association (ADA)/American Geriatrics Society (AGS)/American Pharmacists Association (APhA)/American Society for Preventive Cardiology (ASPC)/National Lipid Association (NLA)/Preventive Cardiovascular Nurses Association (PCNA): Guideline on the management of blood cholesterol (2018)
●AHA: Science advisory on omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease (2017)
●AHA: Scientific statement on meditation and cardiovascular risk reduction (2017)
●AHA: Scientific statement on self-care for the prevention and management of cardiovascular disease and stroke (2017)
●AHA and ADA: Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence (2015)
●AHA/ACC: Guideline on lifestyle management to reduce cardiovascular risk, 2013 (published 2014)
●AHA/ACC/The Obesity Society (TOS): Guideline for the management of overweight and obesity in adults, 2013 (published 2014)
●AHA: Effectiveness-based guidelines for the prevention of cardiovascular disease in women, update (2011)
Europe
●European Society of Cardiology (ESC): Guidelines for the management of cardiovascular disease in patients with diabetes (2023)
●ESC: Guidelines on cardiovascular disease prevention in clinical practice (2021)
●ESC: Guidelines for the management of dyslipidaemias (2019)
United Kingdom
●National Institute for Health and Care Excellence (NICE): Guideline on cardiovascular disease − Risk assessment and reduction, including lipid modification (2023)
●Scottish Intercollegiate Guidelines Network (SIGN): A national clinical guideline on cardiac rehabilitation (2017)
●SIGN: A national clinical guideline on risk estimation and the prevention of cardiovascular disease (2017)
Australia–New Zealand
●Choosing Wisely Australia: Do not prescribe aspirin therapy for primary prevention of cardiovascular disease in patients with stage 1-3 chronic kidney disease as there is no proven benefit and it is associated with increased risk of impaired haemostasis (2021)
●National Heart Foundation of Australia: Position statement on coronary artery calcium scoring for the primary prevention of cardiovascular disease in Australia (2021)
